Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected.
Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Coman-Vlagea N, Della Vecchia A, Horeanga A, Papleux E, Vekemans M, Beukinga I, Blairon L.
Tré-Hardy M, et al. Among authors: wilmet a.
J Infect. 2022 Apr;84(4):e31-e33. doi: 10.1016/j.jinf.2022.02.009. Epub 2022 Feb 16.
J Infect. 2022.
PMID: 35181372
Free PMC article.
No abstract available.